Dr. Patrick Thomas Griffin, MD

Dr. Griffin practices at Texas Oncology PA in Fort Worth, Texas.

Dr. Griffin's NPI, 1386963015, was assigned on May 20, 2010. Dr. Griffin graduated from McGovern Medical School in 2010. Dr. Griffin holds Texas license Q6751.

Dr. Griffin's primary practice is Texas Oncology PA, at 6500 Harris Pkwy, Fort Worth, TX 76132 in Tarrant County. The practice phone is (972) 997-8000.

Dr. Griffin's primary practice is Texas Oncology PA in Fort Worth, Texas. Dr. Griffin is also affiliated with Texas Health Fort Worth. The medical group on file is Texas Oncology. Dmand AI also links Dr. Griffin to 2 more hospitals, 1 group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Griffin practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Griffin's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Griffin is board certified in hematology by the American Board of Internal Medicine. Dr. Griffin is licensed in Texas.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), lung cancer and lymphoma among the conditions Dr. Griffin treats.

CMS data shows 30,183 Medicare services from Dr. Griffin across 59 procedure codes in 2024, for 527 Medicare patients. Medicare paid $471,196 for them.

CMS counts 527 Medicare patients who saw Dr. Griffin in 2024. The largest group is 65 to 74, with 214 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 1.99, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Griffin's median patient age at 70, with 58% women.

In 2024, Dr. Griffin wrote 2,291 Medicare Part D claims for 354 patients. 82% of them were for generic drugs. CMS names the drug for 1,997 of them, across 52 drugs with 11 or more claims each, at $2,319,846 in total drug cost. In 2023, CMS named 1,800 claims across 52 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Griffin for performance year 2024, reported through an alternative payment model (APM). Dr. Griffin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 5 papers to Dr. Griffin, published from 2015 to 2017. 2015 was the busiest year, with 2. The most frequent topics are Induction Chemotherapy, Leukemia, Myeloid, Acute and Remission Induction. Dr. Griffin has published most often in Am J Hematol. Dr. Griffin's most frequent co-authors are Michael Vishal Jaglal, MD, Rami Salah-Eddin Komrokji, MD and Jeffrey E. Lancet, MD.

CMS Open Payments shows 181 general payments to Dr. Griffin from 39 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 96% of the total. Amgen Inc. paid the most, $380.

Dmand AI lists 3 awards for Dr. Griffin, most recently Abstract Achievement Award in 2014.

Dr. Griffin graduated from McGovern Medical School in 2010. Dr. Griffin is a member of AOA, ACP, AMA, ASCO and ASH.

Dr. Griffin is in network with 21 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.